China targets high-technology investment in industry:
This article was originally published in Clinica
Executive Summary
China has implemented a number of measures to make investment in its industry more attractive to overseas companies. Government policy has shifted priority away from promoting specific regions for foreign investment to focusing on particular technology-intensive industries, reports the SPAC. Investment in the central and western parts of China will continue to be "positively encouraged", however. Once approval has been obtained from the State Taxation Administration, foreign-invested enterprises will enjoy a special 15% income tax rate. Overseas companies will be encouraged to invest in existing state-owned enterprises, the SPAC says.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.